Sugi Predict

Sugi Predict / Compounds / SCHEMBL1714716

SCHEMBL1714716

SCHEMBL1714716

NOCC12CC3CC(CC(C3)C1)C2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIN2D O15399 6/20 0.52
▸ GRIN3B O60391 6/20 0.52
▸ GRIN1 Q05586 6/20 0.52
▸ GRIN2A Q12879 6/20 0.52
▸ GRIN2B Q13224 6/20 0.52
▸ GRIN2C Q14957 6/20 0.52
▸ GRIN3A Q8TCU5 6/20 0.52
▸ CA12 O43570 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ ALDH1A1 P00352 3/20 0.41
▸ TSHR P16473 2/20 0.40
▸ LMNA P02545 2/20 0.39
▸ SLC22A2 O15244 1/20 0.39
▸ SLC22A1 O15245 1/20 0.39
▸ NFKB1 P19838 1/20 0.39
▸ STAT6 P42226 1/20 0.39
▸ SLC47A1 Q96FL8 1/20 0.39
▸ SIGMAR1 Q99720 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1715743 0.97 GRIN2D (0.50) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL5095244 0.78 GRIN2D (0.50) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL25222688 0.75 GRIN2D (0.56) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL197070 0.74 GRIN2D (0.48) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL20612578 0.74 CA12 (0.47) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL197069 0.74 CA12 (0.47) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL3227399 0.72 CA12 (0.45) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL855034 0.72 CA12 (0.45) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL3913351 0.72 CA12 (0.45) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL13875115 0.70 GRIN2D (0.43) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 — — US claimed
JP-2007513098-A — — 2007-05-24 — — JP claimed
EP-1697312-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF Leo Pharma A/S (DK) 2006-09-06 — — EP claimed
WO-2005054179-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA A/S (DK) 2005-06-16 — — WO claimed
US-20250243161-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2025-07-31 — — US disclosed
US-12269800-B2 Delivery of therapeutic alkaloid compounds SENSORIUM THERAPEUTICS, INC. (US) 2025-04-08 — — US disclosed
US-20250051277-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2025-02-13 — — US disclosed
US-20240246910-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2024-07-25 — — US disclosed
US-11999694-B2 Delivery of therapeutic alkaloid compounds SENSORIUM THERAPEUTICS, INC. (US) 2024-06-04 — — US disclosed
US-20230159455-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2023-05-25 — — US disclosed
US-20230159455-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2023-05-25 — — US disclosed
US-20230159455-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS SENSORIUM THERAPEUTICS, INC. 2023-05-25 — — US disclosed
US-8034811-B2 Hydroxamic acid esters and pharmaceutical use thereof LEO PHARMA A/S (DK) 2011-10-11 — — US disclosed
EP-1697312-B1 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA AS (DK) 2011-07-20 — — EP disclosed
EP-1697312-B1 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA AS (DK) 2011-07-20 — — EP disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 — — US disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 — — US disclosed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 — — US disclosed
EP-1697312-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF Leo Pharma A/S (DK) 2006-09-06 — — EP disclosed
WO-2005054179-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA A/S (DK) 2005-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051277-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS PNMT, HNMT, NNMT GRIN2D 1862/4885GRIN3B 293/4885GRIN1 783/4885
US-20250243161-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS PNMT, HNMT, NNMT GRIN2D 1862/4885GRIN3B 293/4885GRIN1 783/4885
US-20230159455-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS PNMT, HNMT, NNMT GRIN2D 1862/4885GRIN3B 293/4885GRIN1 783/4885
US-20240246910-A1 DELIVERY OF THERAPEUTIC ALKALOID COMPOUNDS PNMT, HNMT, NNMT GRIN2D 1862/4885GRIN3B 293/4885GRIN1 783/4885
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof F9, F12, HDAC9 GRIN2D 2644/4885GRIN3B 3741/4885GRIN1 2777/4885
US-12269800-B2 Delivery of therapeutic alkaloid compounds PNMT, HNMT, NNMT GRIN2D 1862/4885GRIN3B 293/4885GRIN1 783/4885
US-11999694-B2 Delivery of therapeutic alkaloid compounds PNMT, HNMT, NNMT GRIN2D 1862/4885GRIN3B 293/4885GRIN1 783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.